Continuous use of oral contraceptives: An overview of effects and side-effects

Acta Obstetricia et Gynecologica Scandinavica

Volumn 92, Issue 2, 2013, Pages 125-136

  Hee, Lene ^a   Kettner, Laura Ozer ^a   Vejtorp, Mogens ^b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

benefits; continuous use; menstrual profile; Oral contraceptives; review; side effects

Indexed keywords

CYPROTERONE; DANAZOL; FERRITIN; GONADORELIN; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN; LIPID; NORETHISTERONE ACETATE; ORAL CONTRACEPTIVE AGENT; TRANSFERRIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

BLOOD CLOTTING; BODY WEIGHT; BONE DENSITY; BONE METABOLISM; BONE MINERAL; BONE REMODELING; CHOLESTEROL BLOOD LEVEL; DEEP VEIN THROMBOSIS; DRUG USE; DYSMENORRHEA; DYSPAREUNIA; ENDOMETRIAL THICKNESS; ENDOMETRIOSIS; ENDOMETRIUM ATROPHY; ENDOMETRIUM HYPERPLASIA; ENDOMETRIUM TUMOR; FERRITIN BLOOD LEVEL; FIBRINOLYSIS; FOLLOW UP; HEALTH CARE COST; HEMOGLOBIN BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HOT FLUSH; HUMAN; IRON DEFICIENCY ANEMIA; IRON METABOLISM; LIBIDO DISORDER; LIPID BLOOD LEVEL; LUNG EMBOLISM; MEAN CORPUSCULAR HEMOGLOBIN; MEAN CORPUSCULAR VOLUME; MENSTRUAL CYCLE; META ANALYSIS (TOPIC); METRORRHAGIA; OSTEOPOROSIS; OVARY FOLLICLE DEVELOPMENT; PELVIS PAIN SYNDROME; PREGNANCY RATE; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; PROTEIN EXPRESSION; RECURRENCE RISK; RECURRENT DISEASE; REVIEW; SIDE EFFECT; SPOTTING; TRANSFERRIN BLOOD LEVEL; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; UTERINE CERVIX MUCUS; VENOUS THROMBOEMBOLISM; WEIGHT; WEIGHT GAIN;

BLOOD PRESSURE; BODY WEIGHT; BONE DENSITY; CONTRACEPTIVES, ORAL; ENDOMETRIOSIS; ENDOMETRIUM; FEMALE; HUMANS; MENSTRUATION; PELVIC PAIN; RECURRENCE; VENOUS THROMBOEMBOLISM;

EID: 84872861172     PISSN: 00016349     EISSN: 16000412     Source Type: Journal    
DOI: 10.1111/aogs.12036     Document Type: Review

References (60)

1. Pincus G, Garcia CR, Rock J, Paniagua M, Pendleton A, Laraque F, et al,. Effectiveness of an oral contraceptive; effects of a progestin-estrogen combination upon fertility, menstrual phenomena, and health. Science 1959; 130: 81-3.
2. Kaunitz AM,. Menstruation: choosing whether.and when. Contraception 2000; 62: 277-84.
3. Thomas SL, Ellertson C,. Nuisance or natural and healthy: should monthly menstruation be optional for women Lancet 2000; 355: 922-4.
4. Nelson AL,. Extended-regimen contraception: effects on menstrual symptoms and quality of life. J Fam Pract 2006; 55: S1-8.
5. Oxford University [Internet]. Centre for evidence based medicine. 2011.
6. Klipping C, Duijkers I, Fortier MP, Marr J, Trummer D, Elliesen J,. Long-term tolerability of ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen: Results from a randomised, controlled, multicenter study. J Fam Plann Reprod Health Care 2012; 38: 84-93.
7. Kwiecien M, Edelman A, Nichols MD, Jensen JT,. Bleeding patterns and patient acceptability of standard or continuous dosing regimens of a low-dose oral contraceptive: a randomized trial. Contraception 2003; 67: 9-13.
8. Miller L, Hughes JP,. Continuous combination oral contraceptive pills to eliminate withdrawal bleeding: a randomized trial. Obstet Gynecol 2003; 101: 653-61.
9. Anderson FD, Hait H, Hsiu J, Thompson-Graves AL, Wilborn WH, Williams RF,. Endometrial microstructure after long-term use of a 91-day extended-cycle oral contraceptive regimen. Contraception 2005; 71: 55-9.
10. Anderson FD, Gibbons W, Portman D,. Long-term safety of an extended-cycle oral contraceptive (Seasonale): A 2-year multicenter open-label extension trial. Am J Obstet Gynecol 2006; 195: 92-6.
11. Anderson FD, Feldman R, Reape KZ,. Endometrial effects of a 91-day extended-regimen oral contraceptive with low-dose estrogen in place of placebo. Contraception 2008; 77: 91-6.
12. Johnson JV, Grubb GS, Constantine GD,. Endometrial histology following 1 year of a continuous daily regimen of levonorgestrel 90 μg/ethinyl estradiol 20 μg. Contraception 2007; 75: 23-6.
13. Foidart JM, Sulak PJ, Schellschmidt I, Zimmermann D,. The use of an oral contraceptive containing ethinylestradiol and drospirenone in an extended regimen over 126 days. Contraception 2006; 73: 34-40.
14. Miller L, Notter KM,. Menstrual reduction with extended use of combination oral contraceptive pills: Randomized controlled trial. Obstet Gynecol 2001; 98: 771-8.
15. Anderson FD, Hait H,. A multicenter, randomized study of an extended cycle oral contraceptive. Contraception 2003; 68: 89-96.
16. Wiegratz I, Stahlberg S, Manthey T, Sanger N, Mittmann K, Lange E, et al,. Effect of extended-cycle regimen with an oral contraceptive containing 30 μg ethinylestradiol and 2 mg dienogest on bleeding patterns, safety, acceptance and contraceptive efficacy. Contraception 2011; 84: 133-43.
17. Machado RB, de Melo NR, Maia H Jr,. Bleeding patterns and menstrual-related symptoms with the continuous use of a contraceptive combination of ethinylestradiol and drospirenone: a randomized study. Contraception 2010; 81: 215-22.
18. Klipping C, Duijkers I, Fortier MP, Marr J, Trummer D, Elliesen J,. Contraceptive efficacy and tolerability of ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen: An open-label, multicentre, randomised, controlled study. J Fam Plann Reprod Health Care 2012; 38: 73-83.
19. Archer DF,. Menstrual-cycle-related symptoms: a review of the rationale for continuous use of oral contraceptives. Contraception 2006; 74: 359-66.
20. Kuehl TJ, Speikermann AM, Willis SA, Coffee A, Sulak PJ,. Pituitary-ovarian hormone levels and symptoms in oral contraceptive users: Comparison of a 21/7-day and extended regimen. J Reprod Med Obstet Gynecol 2008; 53: 266-70.
21. Portman DJ, Reape KZ, Hait H, Howard BK,. Reduction in dysmenorrhea severity in women using a 91-day extended regimen oral contraceptive compared to a 28-day regimen oral contraceptive for the treatment of cyclic pelvic pain. Fertil Steril 2011; 96: S110-1.
22. Schlaff WD, Lynch AM, Hughes HD, Cedars MI, Smith DL,. Manipulation of the pill-free interval in oral contraceptive pill users: the effect on follicular suppression. Am J Obstet Gynecol 2004; 190: 943-51.
23. Birtch RL, Olatunbosun OA, Pierson RA,. Ovarian follicular dynamics during conventional vs. continuous oral contraceptive use. Contraception 2006; 73: 235-43.
24. Barnhart KT, Schreiber CA,. Return to fertility following discontinuation of oral contraceptives. Fertil Steril 2009; 91: 659-63.
25. Archer DF, Kovalevsky G, Ballagh SA, Grubb GS,. Ovarian activity and safety of a novel levonorgestrel/ethinyl estradiol continuous oral contraceptive regimen. Contraception 2009; 80: 245-53.
26. Gelbaya TA, Nardo LG,. Evidence-based management of endometrioma. Reprod Biomed Online 2011; 23: 15-24.
27. Vercellini P, Barbara G, Abbiati A, Somigliana E, Vigano P, Fedele L,. Repetitive surgery for recurrent symptomatic endometriosis: what to do Eur J Obstet Gynecol Reprod Biol 2009; 146: 15-21.
28. Vercellini P, De Giorgi O, Mosconi P, Stellato G, Vicentini S, Crosignani PG,. Cyproterone acetate versus a continuous monophasic oral contraceptive in the treatment of recurrent pelvic pain after conservative surgery for symptomatic endometriosis. Fertil Steril 2002; 77: 52-61.
29. Zupi E, Marconi D, Sbracia M, Zullo F, De Vivo B, Exacustos C, et al,. Add-back therapy in the treatment of endometriosis-associated pain. Fertil Steril 2004; 82: 1303-8.
30. Sesti F, Pietropolli A, Capozzolo T, Broccoli P, Pierangeli S, Bollea MR, et al,. Hormonal suppression treatment or dietary therapy versus placebo in the control of painful symptoms after conservative surgery for endometriosis stage III-IV. A randomized comparative trial. Fertil Steril 2007; 88: 1541-7.
31. Kitawaki J, Ishihara H, Kiyomizu M, Honjo H,. Maintenance therapy involving a tapering dose of danazol or mid/low doses of oral contraceptive after gonadotropin-releasing hormone agonist treatment for endometriosis- associated pelvic pain. Fertil Steril 2008; 89: 1831-5.
32. Seracchioli R, Mabrouk M, Frasca C, Manuzzi L, Savelli L, Venturoli S,. Long-term oral contraceptive pills and postoperative pain management after laparoscopic excision of ovarian endometrioma: a randomized controlled trial. Fertil Steril 2010; 94: 464-71.
33. Guzick DS, Huang LS, Broadman BA, Nealon M, Hornstein MD,. Randomized trial of leuprolide versus continuous oral contraceptives in the treatment of endometriosis-associated pelvic pain. Fertil Steril 2011; 95: 1568-73.
34. Sesti F, Capozzolo T, Pietropolli A, Marziali M, Bollea MR, Piccione E,. Recurrence rate of endometrioma after laparoscopic cystectomy: a comparative randomized trial between post-operative hormonal suppression treatment or dietary therapy vs. placebo. Eur J Obstet Gynecol Reprod Biol 2009; 147: 72-7.
35. Seracchioli R, Mabrouk M, Frasca C, Manuzzi L, Montanari G, Keramyda A, et al,. Long-term cyclic and continuous oral contraceptive therapy and endometrioma recurrence: a randomized controlled trial. Fertil Steril 2010; 93: 52-6.
36. Lidegaard O, Kreiner S,. Contraceptives and cerebral thrombosis: a five-year national case-control study. Contraception 2002; 65: 197-205.
37. Lidegaard O, Milsom I, Geirsson RT, Skjeldestad FE,. Hormonal contraception and venous thromboembolism. Acta Obstet Gynecol Scand 2012; 91: 769-78.
38. Lidegaard O, Nielsen LH, Skovlund CW, Skjeldestad FE, Lokkegaard E,. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. Br Med J 2011; 343: d6423.
39. Lidegaard O, Lokkegaard E, Jensen A, Skovlund CW, Keiding N,. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med 2012; 366: 2257-66.
40. Dinger JC, Bardenheuer K, Assmann A,. International Active Surveillance Study of Women Taking Oral Contraceptives (INAS-OC Study). BMC Med Res Methodol 2009; 9: 77.
41. Farley TM, Meirik O, Collins J,. Cardiovascular disease and combined oral contraceptives: reviewing the evidence and balancing the risks. Hum Reprod Update 1999; 5: 721-35.
42. Wiegratz I, Stahlberg S, Manthey T, Sanger N, Mittmann K, Palombo-Kinne E, et al,. Effects of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg dienogest on lipid metabolism during 1 year of conventional or extended-cycle use. Contraception 2010; 81: 57-61.
43. Cachrimanidou AC, Hellberg D, Nilsson S, von Schoulz B, Crona N, Siegbahn A,. Hemostasis profile and lipid metabolism with long-interval use of a desogestrel-containing oral contraceptive. Contraception 1994; 50: 153-65.
44. Machado RB, de Melo NR, Maia H Jr., Cruz AM,. Effect of a continuous regimen of contraceptive combination of ethinylestradiol and drospirenone on lipid, carbohydrate and coagulation profiles. Contraception 2010; 81: 102-6.
45. Wiegratz I, Stahlberg S, Manthey T, Sanger N, Mittmann K, Lange E, et al,. Effects of conventional or extended-cycle regimen of an oral contraceptive containing 30 μg ethinylestradiol and 2 mg dienogest on various hemostasis parameters. Contraception 2008; 78: 384-91.
46. Wiegratz I, Stahlberg S, Manthey T, Sanger N, Mittmann K, Palombo-Kinne E, et al,. Effects of combined oral contraceptive ethinylestradiol (30 μg) and dienogest (2 mg) on carbohydrate metabolism during 1 year of conventional or extended-cycle use. Horm Metab Res 2010; 42: 358-63.
47. Milman N, Clausen J, Byg KE,. Iron status in 268 Danish women aged 18-30 years: influence of menstruation, contraceptive method, and iron supplementation. Ann Hematol 1998; 77: 13-9.
48. Burton JL,. Effect of oral contraceptives on haemoglobin, packed-cell volume, serum-iron, and total iron-binding capacity in healthy women. Lancet 1967; 1: 978-80.
49. Manolagas SC, Kousteni S, Jilka RL,. Sex steroids and bone. Recent Prog Horm Res 2002; 57: 385-409.
50. Nappi C, Di Spiezio Sardo A, Acunzo G, Bifulco G, Tommaselli GA, Guida M, et al,. Effects of a low-dose and ultra-low-dose combined oral contraceptive use on bone turnover and bone mineral density in young fertile women: a prospective controlled randomized study. Contraception 2003; 67: 355-9.
51. Gargano V, Massaro M, Morra I, Formisano C, Di Carlo C, Nappi C,. Effects of two low-dose combined oral contraceptives containing drospirenone on bone turnover and bone mineral density in young fertile women: a prospective controlled randomized study. Contraception 2008; 78: 10-5.
52. Polatti F, Perotti F, Filippa N, Gallina D, Nappi RE,. Bone mass and long-term monophasic oral contraceptive treatment in young women. Contraception 1995; 51: 2214.
53. Pikkarainen E, Lehtonen-Veromaa M, Mottonen T, Kautiainen H, Viikari J,. Estrogen-progestin contraceptive use during adolescence prevents bone mass acquisition: a 4-year follow-up study. Contraception 2008; 78: 226-31.
54. Spona J, Elstein M, Feichtinger W, Sullivan H, Ludicke F, Muller U, et al,. Shorter pill-free interval in combined oral contraceptives decreases follicular development. Contraception 1996; 54: 71-7.
55. Gallo MF, Lopez LM, Grimes DA, Schulz KF, Helmerhorst FM,. Combination contraceptives: effects on weight. Cochrane Database Syst Rev 2011; 9: CD003987.
56. Anthuber S, Schramm GA, Heskamp ML,. Six-month evaluation of the benefits of the low-dose combined oral contraceptive chlormadinone acetate 2 mg/ethinylestradiol 0.03 mg in young women: results of the prospective, observational, non-interventional, multicentre TeeNIS study. Clin Drug Investig 2010; 30: 211-20.
57. Sillem M, Schneidereit R, Heithecker R, Mueck AO,. Use of an oral contraceptive containing drospirenone in an extended regimen. Eur J Contracept Reprod Health Care 2003; 8: 162-9.
58. Hannaford PC, Iversen L, Macfarlane TV, Elliott AM, Angus V, Lee AJ,. Mortality among contraceptive pill users: cohort evidence from Royal College of General Practitioners' Oral Contraception Study. Br Med J 2010; 340: c927.
59. Anderson FD,. Safety and efficacy of an extended-regimen oral contraception utilizing low-dose ethinyl estradiol. Contraception 2006; 74: 355.
60. Aubeny E, Buhler M, Colau JC, Vicaut E, Zadikian M, Childs M,. The Coraliance study: non-compliant behavior. Results after a 6-month follow-up of patients on oral contraceptives. Eur J Contracept Reprod Health Care 2004; 9: 267-277.